Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 3/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28003378 | 0.96 | PARP1 (0.53) | KLK7PARP1PDK1PDK2PDK3 | |
| SCHEMBL9965340 | 0.96 | PARP1 (0.53) | KLK7PARP1PDK1PDK2PDK3 | |
| SCHEMBL4676650 | 0.89 | PDK1 (0.54) | KLK7PARP1PDK1PDK2PDK3 | |
| SCHEMBL3779343 | 0.89 | PDK1 (0.54) | KLK7PARP1PDK1PDK2PDK3 | |
| SCHEMBL30289331 | 0.89 | PDK1 (0.54) | KLK7PARP1PDK1PDK2PDK3 | |
| SCHEMBL1288345 | 0.87 | PDK1 (0.53) | KLK7PARP1PDK1PDK2PDK3 | |
| SCHEMBL15298945 | 0.87 | PDK1 (0.53) | KLK7PARP1PDK1PDK2PDK3 | |
| SCHEMBL6487540 | 0.87 | PDK1 (0.53) | KLK7PARP1PDK1PDK2PDK3 | |
| SCHEMBL4841744 | 0.86 | PDK1 (0.52) | KLK7PARP1PDK1PDK2PDK3 | |
| SCHEMBL2442588 | 0.85 | PDK1 (0.55) | PARP1PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20090203711-A1 | Inhibitors of P38 Map Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203711-A1 | Inhibitors of P38 Map Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203711-A1 | Inhibitors of P38 Map Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2007129036-A1 | INHIBITORS OF P38 MAP KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203711-A1 | Inhibitors of P38 Map Kinase | MAPK1, MAPK3, CNKSR1 | KLK7 4628/4885PARP1 2314/4885PDK1 299/4885 |
| US-20100216802-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | KLK7 2507/4885PARP1 199/4885PDK1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.